PT - JOURNAL ARTICLE AU - Mahapatra, Soumendu AU - Mishra, Rasmita AU - Prasad, Punit AU - Murmu, Krushna Chandra AU - Aggarwal, Shifu AU - Sethi, Manisha AU - Mohapatra, Priyanka AU - Ghosh, Arup AU - Yadav, Rina AU - Dodia, Hiren AU - Ansari, Shamima Azma AU - De, Saikat AU - Singh, Deepak AU - Suryawanshi, Amol AU - Dash, Rupesh AU - Senapati, Shantibhushan AU - Beuria, Tushar K. AU - Chattopadhyay, Soma AU - Syed, Gulam Hussain AU - Swain, Rajeeb AU - Raghav, Sunil K. AU - Parida, Ajay TI - Nanopore 16S rRNA sequencing reveals alterations in nasopharyngeal microbiome and enrichment of <em>Mycobacterium</em> and <em>Mycoplasma</em> in patients with COVID 19 AID - 10.1101/2021.11.10.21266147 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.10.21266147 4099 - http://medrxiv.org/content/early/2021/11/10/2021.11.10.21266147.short 4100 - http://medrxiv.org/content/early/2021/11/10/2021.11.10.21266147.full AB - The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is a major global health concern. This virus infects the upper respiratory tract and causes pneumonia-like symptoms. So far, few studies have shown that respiratory infections alter nasopharyngeal (NP) microbiome diversity and enrich opportunistic pathogens. In this study, we have sequenced the 16S rRNA variable regions, V1 through V9, extracted from NP samples of control and COVID-19 (symptomatic and asymptomatic) participants using the Oxford Nanopore™ technology. Comprehensive bioinformatics analysis investigating the alpha/beta diversities, non-metric multidimensional scaling, correlation studies, canonical correspondence analysis, linear discriminate analysis, and dysbiosis index analysis revealed control and COVID-19-specific NP microbiomes. We observed significant dysbiosis in COVID-19 NP microbiome with abundance of opportunistic pathogens such as Cutibacterium, Corynebacterium, Oerskovia, and Cellulomonas in asymptomatic patients, and of Streptomyces and Mycobacteriaceae family in symptomatic patients. Furthermore, we observed sharp rise in enrichment of opportunistic pathogens in symptomatic patients, with abundance of Mycobacteria and Mycoplasma, which strongly correlated with the occurrences of chest pain and fever. Our findings contribute novel insights regarding emergence of opportunistic pathogens in COVID-19 patients and their relationship with symptoms, suggesting their potential role in coinfections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge the institutes core funding from the Department of Biotechnology (DBT) Government of India. This work was also supported by the ILS flagship project (BT/ILS/Flagship/2019) from DBT Ramalingaswami Re-entry fellowship (BT/RLF/Re-entry/25/2015) and SERB core research grant (CRG/2018/002052). We also acknowledge Biorepository BSL-3 and BSL-2 laboratories qPCR, and DNA-sequencing institutional central core facilities. R.M. S.M. and K.C.M received their fellowships from Ramalingaswami ILS Flagship and SERB core research grant respectively. We thank all the volunteers who provided samples for research purposes.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical permission for nasopharyngeal microbiome study and the biorepository was obtained from the Institutional Ethical Committee (IEC)/Institutional Review Board (IRB) of the Institute of Life Sciences [(102/HEC/2020) and (100/HEC/2020)]. Approval was also obtained from the Institutional Biosafety Committee (IBSC) (V-122-MISC/2007-08/01/2/2.1) for this study and the biorepository (V-122-MISC/2007-08/01) and from the Review Committee on Genetic Manipulations (RCGM) under Department of Biotechnology, Ministry of Science and Technology.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://www.ncbi.nlm.nih.gov/sra/PRJNA774098